Latest On DBV Technologies S.A (DBVT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-04 21:04 EST | News | DBV Technologies GAAP EPS of -$0.22, revenue of $2.2M | N/A |  |
| 2023-04-07 00:17 EST | News | DBV Technologies files for $250M mixed shelf offering | N/A | |
| 2023-03-04 07:15 EST | News | DBV Technologies S.A. (DBVT) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-03 02:40 EST | News | DBV Technologies GAAP EPS of -$1.24, revenue of $4.8M | N/A | |
| 2022-12-23 19:26 EST | News | DBV stock soars 30% as FDA lifts partial hold on phase 3 trial of peanut allergy patch | N/A | |
| 2022-12-19 13:08 EST | News | DBV Technologies: Downgrade And Tax Loss Selling Create A Buying Opportunity | N/A | |
| 2022-12-16 16:06 EST | News | DBV Tech cut to Sell at Goldman on uncertainty to peanut allergy candidate | N/A | |
| 2022-11-06 21:37 EST | News | DBV Technologies S.A. (DBVT) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-03 21:24 EST | News | DBV Technologies GAAP EPS of -$0.18, revenue of $2.07M | N/A | |
| 2022-09-21 20:09 EST | News | FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial | N/A | |
| 2022-08-01 20:44 EST | News | DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M | N/A | |
| 2022-07-07 23:39 EST | News | DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty | N/A | |
| 2022-06-10 09:08 EST | News | DBV Technologies plans to raise $194M via equity financing | N/A | |
| 2022-06-10 09:08 EST | News | DBV Technologies stock extends rally to a second day; co announces $194M financing | N/A | |
| 2022-06-09 05:30 EST | News | DBV Technologies stock dips amid plans to raise $194M via equity financing | N/A | |
| 2022-06-07 22:57 EST | News | DBV Technologies' phase 3 trial for peanut allergy treatment in toddlers meets main goal | N/A | |
| 2022-05-03 07:47 EST | News | DBV Technologies GAAP EPS of -$0.30 beats by $0.10, revenue of $2.55M beats by $1.27M | N/A | |
| 2022-05-03 07:47 EST | News | DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-03-04 17:04 EST | News | DBV Technologies stock slumps 21% amid FY revenue decline, plans on Peanut patch | N/A | |
| 2022-03-03 23:34 EST | News | DBV Technologies GAAP EPS of -$1.78 beats by $0.28, revenue of $5.70M beats by $0.83M | N/A | |
| 2022-03-03 23:33 EST | News | DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-03 06:02 EST | News | DBV Technologies FY 2021 Earnings Preview | N/A | |
| 2021-12-23 06:11 EST | News | DBV recovers some of yesterday's losses on peanut allergy trial; shares up 13% | N/A | |
| 2021-12-21 14:43 EST | News | DBV Technologies falls after updates on Viaskin Peanut patch | N/A | |
| 2021-11-03 05:58 EST | News | Warning: DBVT is at high risk of performing badly | N/A | |
| 2021-10-29 12:11 EST | News | Viaskin peanut allergy therapy fallout continues as DBV down another 16% today | N/A | |
| 2021-10-27 11:06 EST | News | DBV Technologies EPS beats by $0.05 | N/A | |
| 2021-10-27 11:06 EST | News | DBV falls 25% as FDA seeks to review more data for Viaskin Peanut allergy therapy | N/A | |
| 2021-10-16 02:19 EST | News | DBV Technologies up 11% on unusually high volume | N/A | |
| 2021-08-03 05:38 EST | News | DBV Technologies EPS beats by $0.01 | N/A | |
| 2021-08-03 05:38 EST | News | DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-03-19 00:41 EST | Analyst Rating | The Analyst Target Price has increased from $9.37 to $9.43. | Buy | |
| 2021-03-17 23:35 EST | Analyst Rating | The Analyst Target Price has decreased from $9.38 to $9.37. | Neutral | |
| 2021-03-17 15:27 EST | Analyst Rating | The Analyst Target Price has decreased from $9.41 to $9.38. | Neutral | |
| 2021-03-16 23:58 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-16 23:58 EST | Analyst Rating | The Analyst Target Price has increased from $9.31 to $9.41. | Buy | |
| 2021-03-13 22:10 EST | Analyst Rating | The Analyst Target Price has decreased from $9.33 to $9.31. | Neutral | |
| 2021-03-12 22:37 EST | Analyst Rating | The Analyst Target Price has increased from $9.18 to $9.33. | Buy | |
| 2021-03-12 18:20 EST | News | DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-11 22:42 EST | Analyst Rating | The Analyst Target Price has increased from $9.16 to $9.18. | Buy | |
| 2021-03-11 21:04 EST | News | DBV Technologies EPS beats by $0.75, misses on revenue | N/A | |
| 2021-03-11 02:21 EST | Analyst Rating | The Analyst Target Price has increased from $9.13 to $9.16. | Buy | |
| 2021-03-09 22:34 EST | Analyst Rating | The Analyst Target Price has decreased from $9.18 to $9.13. | Neutral | |
| 2021-03-09 10:02 EST | Analyst Rating | The Analyst Target Price has increased from $9.17 to $9.18. | Buy | |
| 2021-03-07 10:02 EST | Analyst Rating | The Analyst Target Price has decreased from $9.21 to $9.17. | Neutral | |
| 2021-03-05 22:30 EST | Analyst Rating | The Analyst Target Price has decreased from $9.28 to $9.21. | Neutral | |
| 2021-03-05 13:45 EST | Analyst Rating | The Analyst Target Price has increased from $9.22 to $9.28. | Buy | |
| 2021-03-04 02:26 EST | Analyst Rating | The Analyst Target Price has increased from $9.19 to $9.22. | Buy | |
| 2021-03-02 22:29 EST | Analyst Rating | The Analyst Target Price has decreased from $9.22 to $9.19. | Neutral | |
| 2021-03-01 22:15 EST | Analyst Rating | The Analyst Target Price has increased from $9.21 to $9.22. | Buy | |
About DBV Technologies S.A (DBVT):
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
General
- Name DBV Technologies S.A
- Symbol DBVT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Fiscal Year EndDecember
- IPO Date2014-10-22
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.dbv-technologies.com
View More
Valuation
- Price/Book (Most Recent Quarter) 2.29
View More
Financials
- Most Recent Quarter 2020-12-31
- Operating Margin -1194%
- Return on Assets -30%
- Return on Equity -77%
- Revenue 11.28 million
- Earnings Per Share -$3.27
- Revenue Per Share $0.1
- Gross Profit 11.28 million
- Quarterly Earnings Growth 32.6%
View More
Highlights
- Market Capitalization 606.86 million
- Analyst Target Price $9.43
- Book Value Per Share $1.88
View More
Share Statistics
- Shares Outstanding 109.78 million
- Shares Float 62.26 million
- % Held by Insiders <1%
- % Held by Institutions 33.81%
- Shares Short 1.39 million
- Shares Short Prior Month 1.45 million
- Short Ratio 4.89
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 2.21
- 52 Week High $7
- 52 Week Low $1.35
- 50 Day Moving Average 5.56
- 200 Day Moving Average 3.3
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
DBV Technologies S.A (DBVT) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
DBV Technologies S.A (DBVT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2019-12-31 | 2020-03-04 | $N/A | -$0.94 | -$1.64 | 42.92% |
| 2019-09-30 | 2019-09-30 | $N/A | -$0.42 | -$0.47 | 10.64% |
| 2017-06-30 | 2017-07-28 | $8.69 million | -$1.46 | -$1.84 | 20.66% |
| 2015-06-30 | 2015-07-27 | $1.97 million | -$0.24 | -$0.53 | 54.47% |
| 2015-03-31 | 2015-04-29 | $1.56 million | -$0.18 | -$0.51 | 65.47% |
| 2014-12-31 | 2015-03-26 | $2.12 million | -$0.65 | -$0.40 | -62.5% |
DBV Technologies S.A (DBVT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
DBV Technologies S.A (DBVT) Chart:
DBV Technologies S.A (DBVT) News:
Below you will find a list of latest news for DBV Technologies S.A (DBVT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
DBV Technologies S.A (DBVT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.05 | CALL | 0 | 37 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0 | PUT | 0 | 0 | 1001.4 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 1115.84 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 1181.39 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.05 | CALL | 0 | 19 | 169.16 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-11-15 | 2.5 | 0.1 | CALL | 0 | 1 | 182.49 | FALSE | 0 | 0 |
| 2024-11-15 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2.5 | 0 | PUT | 0 | 0 | 653 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
Latest DBVT Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:57 PM EST | 1000 | $2.31 |
| Jun 13, 2022 7:57 PM EST | 100 | $2.3 |
| Jun 13, 2022 7:57 PM EST | 100 | $2.31 |
| Jun 13, 2022 7:57 PM EST | 200 | $2.31 |
| Jun 13, 2022 7:58 PM EST | 100 | $2.31 |
DBV Technologies S.A (DBVT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520180920/0001193125-20-180920-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613780/000089542120000079/0000895421-20-000079-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613780/000110259820000012/0001102598-20-000012-index.htm |
| 2019-10-15 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1613780/000110465919054128/0001104659-19-054128-index.htm |
| 2019-10-11 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1613780/000114420419048132/0001144204-19-048132-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613780/000117266120000879/0001172661-20-000879-index.htm |
| 2019-10-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312519262728/0001193125-19-262728-index.htm |
| 2019-10-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1613780/000119312519264551/0001193125-19-264551-index.htm |
| 2019-10-09 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1613780/000119312519264577/0001193125-19-264577-index.htm |
| 2019-10-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1613780/000119312519265115/0001193125-19-265115-index.htm |
| 2019-10-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312519265129/0001193125-19-265129-index.htm |
| 2019-10-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613780/000119312519266778/0001193125-19-266778-index.htm |
| 2019-10-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312519267732/0001193125-19-267732-index.htm |
| 2019-10-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312519273629/0001193125-19-273629-index.htm |
| 2019-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312519284775/0001193125-19-284775-index.htm |
| 2020-01-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520000728/0001193125-20-000728-index.htm |
| 2020-01-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520004087/0001193125-20-004087-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520006362/0001193125-20-006362-index.htm |
| 2020-01-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520018377/0001193125-20-018377-index.htm |
| 2020-01-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520018469/0001193125-20-018469-index.htm |
| 2020-01-29 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1613780/000119312520018497/0001193125-20-018497-index.htm |
| 2020-01-29 | F-3MEF | Registration statement to add securities to prior Form F-3 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520018829/0001193125-20-018829-index.htm |
| 2020-01-30 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520019593/0001193125-20-019593-index.htm |
| 2020-01-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520019634/0001193125-20-019634-index.htm |
| 2020-02-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520024346/0001193125-20-024346-index.htm |
| 2020-02-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520026901/0001193125-20-026901-index.htm |
| 2020-02-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520029885/0001193125-20-029885-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613780/000119312520038321/0001193125-20-038321-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613780/000119312520038333/0001193125-20-038333-index.htm |
| 2020-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520044804/0001193125-20-044804-index.htm |
| 2020-02-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520046839/0001193125-20-046839-index.htm |
| 2020-03-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520061968/0001193125-20-061968-index.htm |
| 2020-03-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520075122/0001193125-20-075122-index.htm |
| 2020-03-20 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520080633/0001193125-20-080633-index.htm |
| 2020-03-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520080766/0001193125-20-080766-index.htm |
| 2020-03-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520091010/0001193125-20-091010-index.htm |
| 2020-04-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520105378/0001193125-20-105378-index.htm |
| 2020-04-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520112342/0001193125-20-112342-index.htm |
| 2020-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520128798/0001193125-20-128798-index.htm |
| 2020-04-30 | F-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1613780/000119312520128894/0001193125-20-128894-index.htm |
| 2020-06-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520163492/0001193125-20-163492-index.htm |
| 2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520180920/0001193125-20-180920-index.htm |
| 2020-07-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520191870/0001193125-20-191870-index.htm |
| 2020-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520206381/0001193125-20-206381-index.htm |
| 2020-08-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520209288/0001193125-20-209288-index.htm |
| 2020-09-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520242192/0001193125-20-242192-index.htm |
| 2020-10-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520282574/0001193125-20-282574-index.htm |
| 2020-11-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613780/000119312520283937/0001193125-20-283937-index.htm |
| 2019-10-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613780/000119380519001334/0001193805-19-001334-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613780/000119380520000186/0001193805-20-000186-index.htm |
| 2019-10-01 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1613780/999999999519002219/9999999995-19-002219-index.htm |